At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AIM AIM ImmunoTech Inc.
Trading 10-28 12:43:25 EDT
0.1681
+0.0019
+1.14%
High0.1697Low0.1652Vol113.81K
Open0.1680D1 Closing0.1662Amplitude2.71%
Mkt Cap6.71MTradable Cap6.37MTotal Shares39.89M
T/O18.98KT/O Rate0.30%Tradable Shares37.90M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

AIM ImmunoTech CEO and President Thomas K Equels Reports Acquisition of $5,093.75 in Common Shares
Reuters  ·  10-24
AIM ImmunoTech CEO and President Thomas K Equels Reports Acquisition of $5,093.75 in Common Shares
Ai-Media Technologies Limited (AIM) Gets a Hold from Morgans
TIPRANKS  ·  10-15
Ai-Media Technologies Limited (AIM) Gets a Hold from Morgans
AIM ImmunoTech Highlights Duripanc Trial Testing Ampligen Plus AstraZeneca’s Imfinzi in Metastatic Pancreatic Cancer Maintenance Therapy
Reuters  ·  10-07
AIM ImmunoTech Highlights Duripanc Trial Testing Ampligen Plus AstraZeneca’s Imfinzi in Metastatic Pancreatic Cancer Maintenance Therapy
AIM ImmunoTech Says Phase 2 Duripanc Pancreatic Cancer Trial Advances Toward Q1 2027 Topline Data
Reuters  ·  10-01
AIM ImmunoTech Says Phase 2 Duripanc Pancreatic Cancer Trial Advances Toward Q1 2027 Topline Data
AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as Duripanc Advances Toward Topline Data
THOMSON REUTERS  ·  10-01
AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as Duripanc Advances Toward Topline Data
AIM ImmunoTech Expects Q1 2027 Topline Data from Phase 2 Duripanc Trial of Ampligen Plus Durvalumab in Metastatic Pancreatic Cancer
Reuters  ·  09-30
AIM ImmunoTech Expects Q1 2027 Topline Data from Phase 2 Duripanc Trial of Ampligen Plus Durvalumab in Metastatic Pancreatic Cancer
AIM ImmunoTech Targets Q1 2027 Topline Data for Phase 2 Duripanc Trial of Ampligen Plus AstraZeneca’s Imfinzi in Pancreatic Cancer
Reuters  ·  09-22
AIM ImmunoTech Targets Q1 2027 Topline Data for Phase 2 Duripanc Trial of Ampligen Plus AstraZeneca’s Imfinzi in Pancreatic Cancer
AIM ImmunoTech CEO Thomas K Equels Acquires Common Shares Worth $4,992
Reuters  ·  09-18
AIM ImmunoTech CEO Thomas K Equels Acquires Common Shares Worth $4,992
AIM ImmunoTech CEO Thomas K. Equels Acquires $4,862 Common Shares
Reuters  ·  09-16
AIM ImmunoTech CEO Thomas K. Equels Acquires $4,862 Common Shares
AIM ImmunoTech Issues 1,921,441 Shares in $450,000 Debt Exchange with Streeterville Capital
Reuters  ·  09-11
AIM ImmunoTech Issues 1,921,441 Shares in $450,000 Debt Exchange with Streeterville Capital
AIM ImmunoTech Advances Phase 2 Duripanc Trial of Ampligen Plus AstraZeneca’s Imfinzi in Pancreatic Cancer
Reuters  ·  09-09
AIM ImmunoTech Advances Phase 2 Duripanc Trial of Ampligen Plus AstraZeneca’s Imfinzi in Pancreatic Cancer
AIM ImmunoTech Issues 5,065,840 Shares in Unregistered Note Exchange with Streeterville Capital
Reuters  ·  09-05
AIM ImmunoTech Issues 5,065,840 Shares in Unregistered Note Exchange with Streeterville Capital
AIM ImmunoTech Expands Ampligen Long COVID Patent Protection Across Europe, UK Through 2041
Reuters  ·  09-02
AIM ImmunoTech Expands Ampligen Long COVID Patent Protection Across Europe, UK Through 2041
AIM ImmunoTech Wins U.S. Patent Covering Ampligen-Keytruda Combo Cancer Therapy Through 2039
Reuters  ·  08-31
AIM ImmunoTech Wins U.S. Patent Covering Ampligen-Keytruda Combo Cancer Therapy Through 2039
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology Ip Protection for Ampligen Through 2039
THOMSON REUTERS  ·  08-31
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology Ip Protection for Ampligen Through 2039
Morgans Sticks to Their Hold Rating for Ai-Media Technologies Limited (AIM)
TIPRANKS  ·  08-28
Morgans Sticks to Their Hold Rating for Ai-Media Technologies Limited (AIM)
Boku Tightens Free Float With Latest Share Buyback on AIM
TIPRANKS  ·  08-27
Boku Tightens Free Float With Latest Share Buyback on AIM
Windar Photonics Directors Deepen Commitment in AIM Fundraise
TIPRANKS  ·  08-27
Windar Photonics Directors Deepen Commitment in AIM Fundraise
Hargreave Hale AIM VCT Tightens Share Base with Buyback and Cancellation
TIPRANKS  ·  08-26
Hargreave Hale AIM VCT Tightens Share Base with Buyback and Cancellation
PetroTal Non‑Executive Director Boosts Stake With AIM Share Purchase
TIPRANKS  ·  08-26
PetroTal Non‑Executive Director Boosts Stake With AIM Share Purchase

Introduction

Company Name.
AIM ImmunoTech Inc.
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Issue price:
--